Summary
This 10-Q filing for Medtronic plc (MDT), for the period ending January 23, 2015, reflects the company's formation and its subsequent significant business combination with Covidien. The financial statements presented are for the newly incorporated entity, 'New Medtronic,' and show minimal operational activity prior to the acquisition. The primary focus of this report is the details surrounding the acquisition of Covidien and the renaming of the combined entity, which became effective on January 26, 2015, with Medtronic plc becoming the successor registrant. Financially, for the period from incorporation to January 23, 2015, the company reported a net loss of $37 million, primarily due to acquisition-related costs. The balance sheet shows minimal assets and liabilities for the new entity itself. The significant event during this period was the consummation of the approximately $50 billion business combination with Covidien. This transaction fundamentally reshaped Medtronic, creating a larger, more diversified medical technology company. The filing details the financing for this transaction, including significant debt issuances, and the subsequent integration efforts that will be crucial for realizing the anticipated benefits of this transformative merger.
Financial Highlights
43 data points| Revenue | $4.32B |
| Cost of Revenue | $1.13B |
| Gross Profit | $3.19B |
| SG&A Expenses | $1.49B |
| Operating Expenses | $37.08M |
| Operating Income | $1.27B |
| Interest Expense | $176.00M |
| Net Income | $977.00M |
| EPS (Basic) | $0.99 |
| EPS (Diluted) | $0.98 |
| Shares Outstanding (Basic) | 983.80M |
| Shares Outstanding (Diluted) | 995.80M |
Key Highlights
- 1The period ending January 23, 2015, marks the formation of Medtronic plc (Ireland) and its subsequent business combination with Covidien, effective January 26, 2015.
- 2The company reported a net loss of $37 million for the period, largely attributed to acquisition-related expenses.
- 3The primary financial event was the completion of a business combination with Covidien, valued at approximately $50 billion, comprising $16 billion in cash and $34 billion in non-cash consideration.
- 4Medtronic plc became the successor registrant to Medtronic, Inc. and Covidien, with shares listed on the NYSE under the symbol 'MDT'.
- 5Significant debt financing was arranged to fund the cash portion of the transaction, including a $3.0 billion term loan and a $3.5 billion revolving credit facility.
- 6The company is undergoing the process of integrating Medtronic and Covidien, with preliminary acquisition valuations for the business combination still being determined.
- 7The filing includes extensive risk factor disclosures related to the integration of the combined entities, regulatory environments, intellectual property, and ongoing legal proceedings for both Medtronic and Covidien.